



## Armored RNA® SARS (CoV-NC)

Catalog #: 42091

### Suggested Use

- Daily controls for RNA extraction, amplification, and detection
- Calibrating controls, proficiency samples, or new assay development

### Packaged SARS (CoV-NC) Sequence

Amplification primer binding regions for SARS (CoV-NC) sequences (Emery et al., 2004) are underlined (see below). The PCR products generated by the N1 and N2 primer set are 67 basepairs and 68 basepairs, respectively.

<u>CCGAAGAGCT</u>	<u>ACCCGACGAG</u>	<u>TTCGTGGTGG</u>	<u>TGACGGCAAA</u>	<u>ATGAAAGAGC</u>
<u>TCAGCCCCAG</u>	<u>ATGGTACTTC</u>	<u>TATTACCTAG</u>	<u>GAAGTGGCCC</u>	<u>AGAAGCTTCA</u>
<u>CTTCCCTACG</u>	<u>GCGCTAACAA</u>	<u>AGAAGGCATC</u>	<u>GTATGGGTTG</u>	<u>CAACTGAGGG</u>
<u>AGCCTTGAAT</u>	<u>ACACCCAAAG</u>	<u>ACCACATTGG</u>	<u>CACCCGCAAT</u>	<u>CCTAATAACA</u>

Emery 2004, **N1** Forward

<u>ATGCTGCCAC</u>	<u>CGTGCTACAA</u>	<u>CTTCCTCAAG</u>	<u>GAACAACATT</u>	<u>GCCAAAAGGC</u>
-------------------	-------------------	-------------------	-------------------	-------------------

Emery 2004, **N1** Reverse

<u>TTCTACGCAG</u>	<u>AGGGAAGCAG</u>	<u>AGGCGGCAGT</u>	<u>CAAGCCTCTT</u>	<u>CTCGCTCCTC</u>
<u>ATCACGTAGT</u>	<u>CGCGGTAATT</u>	<u>CAAGAAATTC</u>	<u>AACTCCTGGC</u>	<u>AGCAGTAGGG</u>
<u>GAAATTCTCC</u>	<u>TGCTCGAATG</u>	<u>GCTAGCGGAG</u>	<u>GTGGTGAAAC</u>	<u>TGCCCTCGCG</u>
<u>CTATTGCTGC</u>	<u>TAGACAGATT</u>	<u>GAACCAGCTT</u>	<u>GAGAGCAAAG</u>	<u>TTTCTGGTAA</u>
<u>AGGCCAACAA</u>	<u>CAACAAGGCC</u>	<u>AAACTGTCAC</u>	<u>TAAGAAATCT</u>	<u>GCTGCTGAGG</u>
<u>CATCTAAAAA</u>	<u>GCCTCGCCAA</u>	<u>AAACGTACTG</u>	<u>CCACAAAACA</u>	<u>GTACAACGTC</u>
<u>ACTCAAGCAT</u>	<u>TTGGGAGACG</u>	<u>TGGTCCAGAA</u>	<u>CAAACCCAAG</u>	<u>GAAATTTTCGG</u>
<u>GGACCAAGAC</u>	<u>CTAATCAGAC</u>	<u>AAGGAACTGA</u>	<u>TTACAAACAT</u>	<u>TGGCCGCAAA</u>

Emery 2004, **N2** Forward

<u>TTGCACAATT</u>	<u>TGCTCCAAGT</u>	<u>GCCTCTGCAT</u>	<u>TCTTTGGAAT</u>	<u>GTCACGCATT</u>
-------------------	-------------------	-------------------	-------------------	-------------------

Emery 2004, **N2** Reverse

G

### References

1. Emery SL, Erdman DD, Meyer RF, Bowen MD, Tong S, Cook B, Holloway BP, McCaustland KA, Rota PA, Bankamp B, Lowe LE, Ksiazek TG, Bellini W, Anderson LJ. Real-time RT-PCR Assay for the SARS-Associated Coronavirus (in press EID). 2004.
2. Pasloske BL, WalkerPeach CR, Obermoeller RD, Winkler M, DuBois DB. Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. *J. Clin. Microbiol.* **36**: 3590-3594. 1998.
3. WalkerPeach CR, Winkler M, DuBois DB, Pasloske BL. Ribonuclease-resistant RNA controls (Armored RNA) for reverse transcription-PCR, branched DNA and genotyping assays for hepatitis C virus. *Clin. Chem.* **45**: 2079-2085. 1999.

Armored RNA® is a technology developed jointly by Ambion, Inc. and Cenetron Diagnostics, LLC (US patents #5,677,124, #5,919,625, #5,939,262, #6,214,982, and #6,399,307). Armored RNA® is a registered trademark of Ambion and Cenetron Diagnostics. Amplicor® and Monitor® are registered trademarks of Roche Molecular Systems. For Research Use Only. Not For Use in Diagnostic Procedures.